Sack Lunch Productions: Recognized Revenues for September Ticket Sales on Track to Top $1.3M
Sep 06, 2017 13:01 pm UTC| Business
SALT LAKE CITY, Sept. 06, 2017 -- Sack Lunch Productions, Inc. (OTCMKTS:SAKL) announces revenue guidance on September sales to illustrate the effectiveness of its new marketing and operational strategies. Sack Lunch,...
Omni-Lite Industries Reports Strong Six Month Financial Results and Significant New Orders
Sep 06, 2017 13:01 pm UTC| Business
Company Reports New Orders of over $1 million USCash Flow From Operations Up 11%, EBITDA Up 18%Net Income Up 19%, EPS Up 28%Gross Margin Expansion of 180 Basis Points LOS ANGELES, Sept. 06, 2017 -- For the six months...
Sep 06, 2017 13:01 pm UTC| Business
FREMONT, Calif., Sept. 06, 2017 -- Identiv, Inc. (NASDAQ:INVE) today announced its partnership with nXient to expand security and identity management solutions in the Australian and New Zealand markets. nXient has...
Sep 06, 2017 13:01 pm UTC| Business
SAN DIEGO, Sept. 06, 2017 -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded two new grants from the...
Armanino Named Sage Intacct VAR Partner of the Year for Sixth Time in Seven Years
Sep 06, 2017 13:01 pm UTC| Business
SAN RAMON, Calif. , Sept. 06, 2017 -- Armanino LLP, one of the top 25 largest accounting and business consulting firms in the U.S., today announced it was named Sage Intacct’s VAR Partner of the Year for the sixth time....
AIM Consulting, Navint and Frazier & Deeter Partner with Pramata to Drive Revenue for Customers
Sep 06, 2017 13:01 pm UTC| Business
BRISBANE, Calif., Sept. 06, 2017 -- Pramata, the commercial relationship operations company, today announced its recent partnerships with AIM Consulting, Navint and Frazier Deeter to provide customers with innovative...
Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference
Sep 06, 2017 13:01 pm UTC| Business
ROCKVILLE, Md., Sept. 06, 2017 -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D....